Answers are grounded in this paper and cite their sources.
COPD-OSA overlap syndrome is a relatively common comorbid respiratory disorder, only becoming more common with rising levels of obesity. This places an increased financial burden on the health care system due to increased rates of hospitalization and mortality.1 Despite the fact that we have an effective therapy for OSA, current data are decidedly lacking in demonstrating a clinical benefit regarding positive airway pressure (PAP) therapy. Prior randomized controlled trials2-4 have failed to show a long-term benefit regarding PAP therapy.
No takes yet. Share an insight, caveat, or question.
Baskaran et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: